BeyondSpring stock has increased by 250 percent as a cancer drug outperforms chemotherapy.
BeyondSpring (BYSI) stock more than tripled to a record high after the company said on Wednesday that a cancer drug-based combination outperformed chemotherapy alone in lung cancer patients.
In patients with a kind of lung cancer, the business tested a treatment regimen containing plinabulin against chemotherapy. The treatment enhanced overall survival and other disease indicators while avoiding a potentially fatal chemo side effect.
BeyondSpring has announced that it is intending to apply for plinabulin approval in the United States and China. The findings also pave the way for plinabulin to be utilised in combination with immuno-oncology medicines in the future, broadening its potential applications.
BYSI shares soared 247.3 percent in premarket trading on the stock market today, trading near 33.40. Shares closed below 10 on Tuesday.